Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study.
Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Cleanthous S, et al. Mult Scler J Exp Transl Clin. 2018 May 17;4(2):2055217318776990. doi: 10.1177/2055217318776990. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 29796290 Free PMC article.
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study.
Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY. Strzok S, et al. Among authors: castrillo viguera c. Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783766. doi: 10.1177/2055217318783766. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 30090638 Free PMC article.
Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD, Mokliatchouk O, Castrillo-Viguera C, Naylor ML. Newsome SD, et al. Among authors: castrillo viguera c. Mult Scler Relat Disord. 2020 May;40:101954. doi: 10.1016/j.msard.2020.101954. Epub 2020 Jan 17. Mult Scler Relat Disord. 2020. PMID: 32078948 Free article. Clinical Trial.
Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.
Kantarci OH, Zeydan B, Atkinson EJ, Conway BL, Castrillo-Viguera C, Rodriguez M. Kantarci OH, et al. Among authors: castrillo viguera c. Neurol Neuroimmunol Neuroinflamm. 2019 Dec 17;7(2):e653. doi: 10.1212/NXI.0000000000000653. Print 2020 Mar. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31848231 Free PMC article.
Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C, Castrillo-Viguera C, Sandrock A, Budd Haeberlein S, van Dyck CH, Huttner A. Plowey ED, et al. Among authors: castrillo viguera c. Acta Neuropathol. 2022 Jul;144(1):143-153. doi: 10.1007/s00401-022-02433-4. Epub 2022 May 17. Acta Neuropathol. 2022. PMID: 35581440 Free PMC article.
16 results